Embracing Bayesian Methods in Clinical Trials
https://jamanetwork.com/journals/jama/fullarticle/2847011
This Perspective discusses the importance of the US Food and Drug Administration’s draft guidance on the use of bayesian methods in clinical trials because it underscores its commitment to modernizing clinical research.
https://jamanetwork.com/journals/jama/fullarticle/2847011
This Perspective discusses the importance of the US Food and Drug Administration’s draft guidance on the use of bayesian methods in clinical trials because it underscores its commitment to modernizing clinical research.
Error in Conclusions
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846954
In the Original Investigation titled “Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial,” published online March 16, 2026, there was an error in the Conclusions section. The first sentence should have read, “In this trial, pregnant adults with OUD who were randomized to receive extended-release buprenorphine had higher rates of illicit opioid abstinence during pregnancy than those randomized to receive sublingual buprenorphine.” This article has been corrected.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846954
In the Original Investigation titled “Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial,” published online March 16, 2026, there was an error in the Conclusions section. The first sentence should have read, “In this trial, pregnant adults with OUD who were randomized to receive extended-release buprenorphine had higher rates of illicit opioid abstinence during pregnancy than those randomized to receive sublingual buprenorphine.” This article has been corrected.
Incidence, Predictors, Management, and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847047
This study evaluates the incidence, predictors, management, and clinical outcomes of major bleeding after left atrial appendage occlusion in the Amulet IDE trial.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847047
This study evaluates the incidence, predictors, management, and clinical outcomes of major bleeding after left atrial appendage occlusion in the Amulet IDE trial.
Oral GLP-1 Therapies—Moving Beyond Needles
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847046
Over the past 2 decades, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the therapeutic landscape for cardiovascular, kidney, and metabolic (CKM) care. Since the approval of the first GLP-1 RA (exenatide) in 2005 by the US Food and Drug Administration (FDA), randomized trials have demonstrated benefit across a variety of CKM conditions. However, most of this evidence is based on data from injectable GLP-1–based therapies. To date, semaglutide is the only GLP-1 agent with an approved oral formulation. Given that use of oral semaglutide will inevitably increase, particularly with recent FDA approval for weight management on January 5, 2026, there is a growing need to understand the impact of oral semaglutide on cardiovascular risk factors.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847046
Over the past 2 decades, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the therapeutic landscape for cardiovascular, kidney, and metabolic (CKM) care. Since the approval of the first GLP-1 RA (exenatide) in 2005 by the US Food and Drug Administration (FDA), randomized trials have demonstrated benefit across a variety of CKM conditions. However, most of this evidence is based on data from injectable GLP-1–based therapies. To date, semaglutide is the only GLP-1 agent with an approved oral formulation. Given that use of oral semaglutide will inevitably increase, particularly with recent FDA approval for weight management on January 5, 2026, there is a growing need to understand the impact of oral semaglutide on cardiovascular risk factors.
National Prescribing Trends of Direct-Acting Antivirals for Hepatitis C
https://jamanetwork.com/journals/jama/fullarticle/2846850
This study measures changes in patient and prescriber characteristics for direct-acting antivirals to treat hepatitis C virus infection from 2013 to 2025 in the US.
https://jamanetwork.com/journals/jama/fullarticle/2846850
This study measures changes in patient and prescriber characteristics for direct-acting antivirals to treat hepatitis C virus infection from 2013 to 2025 in the US.
Caring for Adult Patients With Sepsis
https://jamanetwork.com/journals/jama/fullarticle/2847173
This JAMA Clinical Guidelines Synopsis summarizes the newly released Surviving Sepsis Campaign guidelines from ESICM and SCCM detailing treatment recommendations for adults with sepsis, including antimicrobial therapy and management of fluids.
https://jamanetwork.com/journals/jama/fullarticle/2847173
This JAMA Clinical Guidelines Synopsis summarizes the newly released Surviving Sepsis Campaign guidelines from ESICM and SCCM detailing treatment recommendations for adults with sepsis, including antimicrobial therapy and management of fluids.
Patient Information: Stillbirth
https://jamanetwork.com/journals/jama/fullarticle/2846869
This JAMA Patient Page describes the causes, risk factors, and methods for evaluating stillbirth before and after it occurs.
https://jamanetwork.com/journals/jama/fullarticle/2846869
This JAMA Patient Page describes the causes, risk factors, and methods for evaluating stillbirth before and after it occurs.
The Language of Loss
https://jamanetwork.com/journals/jama/fullarticle/2846868
In this narrative medicine essay, a palliative care physician discusses the impact that the death of her brother had on her time as an attending physician working in the emergency department.
https://jamanetwork.com/journals/jama/fullarticle/2846868
In this narrative medicine essay, a palliative care physician discusses the impact that the death of her brother had on her time as an attending physician working in the emergency department.
Errors in Table
https://jamanetwork.com/journals/jama/fullarticle/2846878
The Original Investigation titled “Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial,” published on December 12, 2025, was corrected to update values throughout the Table. This article was corrected online.
https://jamanetwork.com/journals/jama/fullarticle/2846878
The Original Investigation titled “Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial,” published on December 12, 2025, was corrected to update values throughout the Table. This article was corrected online.
The Geography of Pharmaceutical Innovation
https://jamanetwork.com/journals/jama/fullarticle/2846877
China’s rise as a major center of drug development represents one of the most consequential shifts in the global life sciences landscape in a generation. From the patient perspective, a key policy question is how China’s expanding capacity, spanning follow-on products that are based on an approved drug to first-in-class innovation, can be integrated into regulatory frameworks to ensure timely and equitable access to medicines.
https://jamanetwork.com/journals/jama/fullarticle/2846877
China’s rise as a major center of drug development represents one of the most consequential shifts in the global life sciences landscape in a generation. From the patient perspective, a key policy question is how China’s expanding capacity, spanning follow-on products that are based on an approved drug to first-in-class innovation, can be integrated into regulatory frameworks to ensure timely and equitable access to medicines.
The Physician and the Patient of the Future
https://jamanetwork.com/journals/jama/fullarticle/2846876
Wendell C. Phillips, M.D., New York
https://jamanetwork.com/journals/jama/fullarticle/2846876
Wendell C. Phillips, M.D., New York
WHO Guideline on GLP-1 Therapies for Treatment of Obesity in Adults
https://jamanetwork.com/journals/jama/fullarticle/2846874
To the Editor The recent WHO guideline on use of GLP-1 therapies by Dr Celletti and colleagues framed obesity as a chronic, relapsing disease requiring sustained treatment. While this guideline focused on the general adult population, we contend that its proposed “highest need” prioritization framework must explicitly include solid organ (heart, kidney, liver, lung, pancreas, and small bowel) transplant candidates and recipients. This group represents a uniquely vulnerable and underserved population that comprises a significant subset of patients with chronic diseases. In the US alone, there are currently more than 100 000 candidates on solid organ transplant waiting lists, while approximately 500 000 patients are living with a functional solid organ transplant.
https://jamanetwork.com/journals/jama/fullarticle/2846874
To the Editor The recent WHO guideline on use of GLP-1 therapies by Dr Celletti and colleagues framed obesity as a chronic, relapsing disease requiring sustained treatment. While this guideline focused on the general adult population, we contend that its proposed “highest need” prioritization framework must explicitly include solid organ (heart, kidney, liver, lung, pancreas, and small bowel) transplant candidates and recipients. This group represents a uniquely vulnerable and underserved population that comprises a significant subset of patients with chronic diseases. In the US alone, there are currently more than 100 000 candidates on solid organ transplant waiting lists, while approximately 500 000 patients are living with a functional solid organ transplant.
Geographic Shifts in Early-Stage Biopharmaceutical Innovation
https://jamanetwork.com/journals/jama/fullarticle/2846875
This study examines changes from 2015 through 2025 in the country of origin of early-stage biopharmaceutical development programs worldwide.
https://jamanetwork.com/journals/jama/fullarticle/2846875
This study examines changes from 2015 through 2025 in the country of origin of early-stage biopharmaceutical development programs worldwide.
FDA Approves New Generic Inhaler for Asthma Treatment
https://jamanetwork.com/journals/jama/fullarticle/2847171
The US Food and Drug Administration (FDA) approved the first generic version of fluticasone propionate inhalation aerosol, marketed as Flovent HFA, for maintenance treatment of asthma.
https://jamanetwork.com/journals/jama/fullarticle/2847171
The US Food and Drug Administration (FDA) approved the first generic version of fluticasone propionate inhalation aerosol, marketed as Flovent HFA, for maintenance treatment of asthma.
Audio Highlights March 27, 2026
https://jamanetwork.com/journals/jama/fullarticle/2847276
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
https://jamanetwork.com/journals/jama/fullarticle/2847276
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
Practice-Changing Updates in the New Lipid Guidelines
https://jamanetwork.com/journals/jama/fullarticle/2847164
This Medical News article discusses updated cholesterol and triglyceride management recommendations from the American College of Cardiology and the American Heart Association.
https://jamanetwork.com/journals/jama/fullarticle/2847164
This Medical News article discusses updated cholesterol and triglyceride management recommendations from the American College of Cardiology and the American Heart Association.
AHA Calls for Better Recognition of Heart Attacks in Younger Women
https://jamanetwork.com/journals/jama/fullarticle/2847165
This Medical News article discusses a new scientific statement from the American Heart Association on acute coronary syndromes in premenopausal women.
https://jamanetwork.com/journals/jama/fullarticle/2847165
This Medical News article discusses a new scientific statement from the American Heart Association on acute coronary syndromes in premenopausal women.
Exploring Additional Cardiorenal Outcomes
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847049
The rapid expansion of incretin-based therapies has opened new avenues for improving cardiovascular and kidney outcomes for patients with type 2 diabetes, obesity, chronic kidney disease, and heart failure. As the therapeutic landscape evolves, clinicians and investigators increasingly seek clarity not only on primary cardiovascular efficacy but also on the broader constellation of outcomes that matter to patients. In this issue, a post hoc analysis from a large, multinational randomized trial comparing tirzepatide with dulaglutide in patients with type 2 diabetes offers an opportunity to further examine whether a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist may deliver incremental benefit, compared with a GLP-1 receptor agonist alone, when the scope of evaluation of composite cardiorenal outcomes widens. The investigators explore whether superiority emerges when an expanded set of clinically relevant events are evaluated.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847049
The rapid expansion of incretin-based therapies has opened new avenues for improving cardiovascular and kidney outcomes for patients with type 2 diabetes, obesity, chronic kidney disease, and heart failure. As the therapeutic landscape evolves, clinicians and investigators increasingly seek clarity not only on primary cardiovascular efficacy but also on the broader constellation of outcomes that matter to patients. In this issue, a post hoc analysis from a large, multinational randomized trial comparing tirzepatide with dulaglutide in patients with type 2 diabetes offers an opportunity to further examine whether a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist may deliver incremental benefit, compared with a GLP-1 receptor agonist alone, when the scope of evaluation of composite cardiorenal outcomes widens. The investigators explore whether superiority emerges when an expanded set of clinically relevant events are evaluated.
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847048
This parallel-design double-blind trial includes a post hoc analysis of data for patients with type 2 diabetes and cardiovascular disease to compare the incidence of an expanded range of cardiorenal adverse events for tirzepatide vs dulaglutide.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847048
This parallel-design double-blind trial includes a post hoc analysis of data for patients with type 2 diabetes and cardiovascular disease to compare the incidence of an expanded range of cardiorenal adverse events for tirzepatide vs dulaglutide.
Lipid-Lowering Therapy
https://jamanetwork.com/journals/jama/fullarticle/2847163
Preventive cardiology has come a long way since the 1984 landmark publication of the Lipid Research Clinics–Coronary Primary Prevention Trial (LRC-CPPT). Despite considerable evidence supporting the lipid hypothesis of atherogenesis, there was skepticism about whether cholesterol-lowering drug treatment would be beneficial. Robert Levy, director of the National Heart, Lung, and Blood Institute at the time of the LRC-CPPT trial, wrote an editorial in 1985 with a title that is still relevant today—“Cholesterol and Cardiovascular Disease: No Longer Whether, But Rather When, in Whom, and How?”
https://jamanetwork.com/journals/jama/fullarticle/2847163
Preventive cardiology has come a long way since the 1984 landmark publication of the Lipid Research Clinics–Coronary Primary Prevention Trial (LRC-CPPT). Despite considerable evidence supporting the lipid hypothesis of atherogenesis, there was skepticism about whether cholesterol-lowering drug treatment would be beneficial. Robert Levy, director of the National Heart, Lung, and Blood Institute at the time of the LRC-CPPT trial, wrote an editorial in 1985 with a title that is still relevant today—“Cholesterol and Cardiovascular Disease: No Longer Whether, But Rather When, in Whom, and How?”